Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae

Journal of Hospital Infection

Volumn 83, Issue 4, 2013, Pages 307-313

  Hussein, K ^a,b   Raz Pasteur, A ^a,b   Finkelstein, R ^a,b   Neuberger, A ^a   Shachor Meyouhas, Y ^a,b   Oren, I ^a,b   Kassis, I ^a,b  

^a Infectious Diseases Unit   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Carbapenem resistance; Comorbidity; Klebsiella pneumoniae; Mortality; Risk factors

Indexed keywords

AMINOGLYCOSIDE; CARBAPENEM; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; COLISTIN; GENTAMICIN; MACROLIDE; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; TIGECYCLINE; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; CHARLSON COMORBIDITY INDEX; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EXPOSURE; DRUG USE; FEMALE; HEALTH STATUS; HEMODIALYSIS; HOSPITAL INFECTION; HUMAN; INFECTION RISK; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NONHUMAN; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; BETA-LACTAM RESISTANCE; CARBAPENEMS; CASE-CONTROL STUDIES; CROSS INFECTION; FEMALE; HUMANS; ISRAEL; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875386814     PISSN: 01956701     EISSN: 15322939     Source Type: Journal    
DOI: 10.1016/j.jhin.2012.10.012     Document Type: Article

References (25)

1. Bratu S., Landman D., Haag R., et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Archs Intern Med 2005, 165:1430-1435.
2. Souli M., Galani I., Antoniadou A., et al. An outbreak of infection due to beta-lactamase Klebsiella pneumoniae Carbapenemase 2-producing K. pneumoniae in a Greek university hospital molecular characterization, epidemiology, and outcomes. Clin Infect Dis 2010, 50:364-373.
3. Kassis-Chikhani N., Decré D., Gautier V., et al. First outbreak of multidrug-resistant Klebsiella pneumoniae-carrying blaVIM-1 and blaSHV-5 in a French university hospital. J Antimicrob Chemother 2006, 57:142-145.
4. Cagnacci S., Gualcp L., Roveta S., et al. Bloodstream infections caused by multidrug-resistant Klebsiella pneumoniae producing the carbapenem hydrolyzing VIM-1 metallo-β-lactamase: first Italian outbreak. J Antimicrob Chemother 2008, 61:296-300.
5. Psichogiou M., Tassios P.T., Avlamis A., et al. Ongoing epidemic of blaVIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey. J Antimicrob Chemother 2008, 61:59-63.
6. Tato M., Coque T.M., Ruíz-Garbajosa P., et al. Complex clonal and plasmid epidemiology in the first outbreak of Enterobacteriaceae infection involving VIM-1 metallo-β-lactamase in Spain: toward endemicity?. Clin Infect Dis 2007, 45:1171-1178.
7. Paterson D.L. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Med 2006, 119(Suppl. 1):S20-S28.
8. Hirsch E.B., Tam V.H. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010, 65:119-1125.
9. Hussein K., Sprecher H., Mashiach T., Oren I., Kassis I., Finkelstein R. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol 2009, 30:666-671.
10. Samra Z., Ofir O., Lichtzinsky Y., Madar-Shapito L., Bishara J. Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel. Int J Antimicrob Agents 2007, 30:525-529.
11. Leavitt A., Navon-Venezia S., Chmelnitsky I., Schwaber M.J., Carmeli Y. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob Agents Chemother 2007, 51:3026-3029.
12. Patel G., Huprikar S., Factor S.H., Jenkins S.G., Calfee P. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008, 29:1099-1106.
13. Davey P.G., Marwick C. Appropriate vs. inappropriate antimicrobial therapy. Clin Microbiol Infect 2008, 14(Suppl. 3):15-21.
14. Schwaber M., Klarfeld-Lidji S., Navon-Venezia S., Schwartz D., Leavitt A., Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008, 52:1028-1033.
15. Falagas M.E., Rafailidis P.I., Kofteridis D., et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case-control study. J Antimicrob Chemother 2007, 60:1124-1130.
16. Bore A., Saidel-Odes L., Riesenberg K., et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol 2009, 30:972-976.
17. Performance standards for antimicrobial susceptibility testing: 16th informational supplement 2006, Clinical and Laboratory Standards Institute, CLSI, Wayne PA, M100-MS16.
18. Kotlovsky T., Shalginov R., Austin L., Sprecher H. Rapid detection of blaKPC-positive Klebsiella pneumoniae in clinical setting. Eur J Clin Microbiol 2009, 29:309-311.
19. Kuhar DT, Calfee DP. Risk factors for colonization and/or infection with carbapenem-resistant Klebsiella pneumoniae. In: 17th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America; Baltimore, Maryland, USA, 14-17 April 2007. Abstract 251.
20. Ahmad M., Urban C., Mariano N., et al. Clinical characteristics and molecular epidemiology associated with imipenem-resistant Klebsiella pneumoniae. Clin Infect Dis 1999, 29:352-355.
21. Kwak Y.G., Choi S.H., Choo E.J., et al. Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae among hospitalized patients. Microb Drug Resist 2005, 11:165-169.
22. Nguyen M., Eschenauer G., Bryan M., et al. Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. Diagn Microbiol Infect Dis 2010, 67:180-184.
23. Daikos G.L., Petrikkos P., Psichogiou M., et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother 2009, 53:1868-1873.
24. Gross P.A., DeMauro P.J., Van Antwerpen C., Wallenstein S., Chiang S. Number of comorbidities as a predictor of nosocomial infection acquisition. Infect Control Hosp Epidemiol 1988, 9:497-500.
25. Pittet D., Thiévent B., Wenzel R.P., Li N., Gurman G., Suter P.M. Importance of pre-existing comorbidities for prognosis of septicemia in critically ill patients. Intens Care Med 1993, 19:265-272.